Decode Age, a science-driven longevity company focused on ageing biology, biomarker innovation, and gut microbiome research, has secured ₹14.48 crore in a Pre-Series A funding round. The investment was led by Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited, a veteran pharmaceutical leader with more than four decades of experience in innovation-led manufacturing and global scale operations.
This funding marks a significant milestone in Decode Age’s vision to transform how ageing is understood, measured, and managed. The company aims to translate complex biological data into practical, science-backed solutions that enable healthier and longer lives through a microbiome-centric longevity ecosystem.
Building a Science-First Longevity Platform
Decode Age has developed an integrated research platform spanning multi-omics testing, biomarker discovery, and precision-based health interventions. Central to this platform is one of India’s most sophisticated whole-genome gut microbiome analysis systems. The technology delivers high-resolution insights into microbial composition and function, helping decode how the gut microbiome influences immunity, metabolism, inflammation, and ageing-related biological pathways.
The company’s laboratory processes are designed for accuracy, consistency, and reproducibility, supporting use cases across research, clinical practice, and individual health assessment. By combining advanced analytics with biological depth, Decode Age enables a deeper understanding of human ageing at the molecular level.
Advancing Research-Driven Longevity Solutions
Using insights generated from ageing biology and microbiome data, Decode Age is developing a new class of research-led supplements and longevity solutions. These formulations are designed to support healthy ageing by targeting biological mechanisms associated with age-related conditions such as cancer, neurodegenerative disorders, and chronic metabolic diseases—while remaining aligned with established scientific evidence and regulatory frameworks.
The newly raised capital will be deployed to expand biomarker discovery initiatives, accelerate multi-omics and microbiome research programmes, and strengthen the company’s scientific and analytical infrastructure. Investment will also support formulation research aligned with key hallmarks of ageing, including cellular energy optimisation, metabolic regulation, inflammation control, and cognitive health. Additionally, Decode Age plans to deepen collaboration across the global longevity research ecosystem.
Leadership Perspectives
Commenting on the funding, Parth Amin, CEO and Co-founder of Decode Age, said the investment represents a major step forward for the company’s mission.
“This funding reinforces our commitment to bringing scientific clarity and precision to how people understand their own biology. Dr. Chigurupati’s support enables us to advance our research in ageing and gut microbiome science, scale our biomarker programmes, and strengthen the scientific backbone of our work. We remain focused on converting rigorous research into meaningful insights that empower long-term health decisions,” he said.
Dr. Krishna Prasad Chigurupati echoed this confidence in Decode Age’s long-term potential.
“Decode Age is operating at the frontier of science that will reshape how we think about health, disease, and ageing. Their work in ageing biology and microbiome research is both robust and forward-looking, offering biological insights that were previously out of reach for individuals and clinicians. This investment reflects my belief in their scientific approach and the impact they are building for the future,” he stated.
Expanding India’s Role in Global Longevity Science
As it enters its next phase of growth, Decode Age is assembling a world-class team across scientific research, clinical development, and product innovation. The company aims to take India’s longevity innovation to global markets, positioning the country as a key contributor to microbiome science and healthy ageing research.
Decode Age is also actively contributing to the broader longevity ecosystem through collaborations with leading academic and global research initiatives. These include partnerships with the Indian Institute of Science and international programmes such as XPRIZE, where the company supports microbiome-linked data generation, advanced analytics, and longevity-focused therapeutic research. Such collaborations strengthen its ability to connect academic discovery with real-world applications.
Strong Foundations for Future Scale
Founded in 2021, Decode Age has rapidly built advanced metagenomics and microbiome laboratories, introduced whole-genome microbiome analysis for individuals, and launched precision-designed formulations informed by ageing biology. These achievements form a strong base as the company scales its integrated longevity ecosystem—connecting laboratories, clinicians, research partners, and individuals through science-backed solutions.
About Decode Age
Decode Age is India’s first science-led longevity organisation dedicated to enhancing human healthspan through microbiome research, biomarker-based testing, and precision-focused interventions. Established in 2021, the company combines biotechnology, metagenomics, and computational biology to develop research-driven longevity solutions that make complex biology accessible, actionable, and impactful for individuals and partners alike.
